[go: up one dir, main page]

FR2777015B3 - Procede et moyens pour l'obtention de modeles cellulaires et animaux de maladies neurodegeneratives - Google Patents

Procede et moyens pour l'obtention de modeles cellulaires et animaux de maladies neurodegeneratives

Info

Publication number
FR2777015B3
FR2777015B3 FR9802145A FR9802145A FR2777015B3 FR 2777015 B3 FR2777015 B3 FR 2777015B3 FR 9802145 A FR9802145 A FR 9802145A FR 9802145 A FR9802145 A FR 9802145A FR 2777015 B3 FR2777015 B3 FR 2777015B3
Authority
FR
France
Prior art keywords
animal models
neurodegenerative diseases
obtaining cellular
cellular
obtaining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR9802145A
Other languages
English (en)
Other versions
FR2777015A1 (fr
Inventor
Fabien Schweighoffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FINANC DE BIOTECHNOLOGIE
Original Assignee
FINANC DE BIOTECHNOLOGIE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FINANC DE BIOTECHNOLOGIE filed Critical FINANC DE BIOTECHNOLOGIE
Priority to FR9802145A priority Critical patent/FR2777015B3/fr
Priority to JP11038522A priority patent/JPH11285382A/ja
Priority to DE19907493A priority patent/DE19907493A1/de
Priority to GB9903955A priority patent/GB2335192A/en
Publication of FR2777015A1 publication Critical patent/FR2777015A1/fr
Application granted granted Critical
Publication of FR2777015B3 publication Critical patent/FR2777015B3/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
FR9802145A 1998-02-23 1998-02-23 Procede et moyens pour l'obtention de modeles cellulaires et animaux de maladies neurodegeneratives Expired - Lifetime FR2777015B3 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR9802145A FR2777015B3 (fr) 1998-02-23 1998-02-23 Procede et moyens pour l'obtention de modeles cellulaires et animaux de maladies neurodegeneratives
JP11038522A JPH11285382A (ja) 1998-02-23 1999-02-17 神経変性疾患の細胞及び動物モデルを獲得するための方法及び手段
DE19907493A DE19907493A1 (de) 1998-02-23 1999-02-22 Verfahren zum Erhalten von Zell- und Tiermodellen neurodegenerativer Erkrankungen und Mittel zur Durchführung dieser Verfahren
GB9903955A GB2335192A (en) 1998-02-23 1999-02-23 Models for neurodegenerative diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9802145A FR2777015B3 (fr) 1998-02-23 1998-02-23 Procede et moyens pour l'obtention de modeles cellulaires et animaux de maladies neurodegeneratives

Publications (2)

Publication Number Publication Date
FR2777015A1 FR2777015A1 (fr) 1999-10-08
FR2777015B3 true FR2777015B3 (fr) 2000-09-15

Family

ID=9523246

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9802145A Expired - Lifetime FR2777015B3 (fr) 1998-02-23 1998-02-23 Procede et moyens pour l'obtention de modeles cellulaires et animaux de maladies neurodegeneratives

Country Status (4)

Country Link
JP (1) JPH11285382A (fr)
DE (1) DE19907493A1 (fr)
FR (1) FR2777015B3 (fr)
GB (1) GB2335192A (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
JP2005231998A (ja) * 2000-02-01 2005-09-02 Zeria Pharmaceut Co Ltd 透析アミロイド線維重合核の製造方法及び透析アミロイド−シス治療剤のスクリーニング方法並びに透析アミロイドーシス治療剤
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
JP2008523815A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
EP1838854B1 (fr) 2004-12-15 2012-10-31 Janssen Alzheimer Immunotherapy Anticorps reconnaissant le peptide beta amyloide
CN1325652C (zh) * 2005-10-13 2007-07-11 上海交通大学 提高外源蛋白在转基因植物中累积的方法
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009125646A1 (fr) 2008-04-09 2009-10-15 財団法人東京都医学研究機構 Modèle de cellule de stockage de tdp-43
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316727D0 (en) * 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease

Also Published As

Publication number Publication date
DE19907493A1 (de) 1999-08-26
FR2777015A1 (fr) 1999-10-08
GB2335192A (en) 1999-09-15
GB9903955D0 (en) 1999-04-14
JPH11285382A (ja) 1999-10-19

Similar Documents

Publication Publication Date Title
FR2777015B3 (fr) Procede et moyens pour l'obtention de modeles cellulaires et animaux de maladies neurodegeneratives
EP1129333A4 (fr) Procede et dispositif d'adaptation pour modeles d'etalonnage spectroscopique
EP0710675A3 (fr) Méthode améliorée pour l'obtention de polymères
BR9505870A (pt) Método e aparelho de fundição continua de cilindro duplo
DE69610132D1 (de) Druckgussverfahren
NO975690L (no) Fremgangsmåte for forbedring av dyrehelse
FR2747304B1 (fr) Procede de fabrication d'un dispositif exothermique pour rechauffer les pieds et dispositif exothermique pour rechauffer les pieds
FR2787587B1 (fr) Procede pour l'elaboration en temps reel de trajectoires pour un aeronef
EP1212073A4 (fr) Procede de mesure de l'activite du facteur coagulant
DK154097A (da) Apparat til human aflivning af fisk
EP1120841A4 (fr) Procede et structure pour la connexion de batteries
EP0833814A4 (fr) Procede de preparation d'hydroxyalkylamides
EP1222865A4 (fr) Ingredient pour cigarette et procede de fabrication
BR9604635A (pt) Método e aparelho para fabricar moldes
FR2753986B1 (fr) Lubrifiant pour hypercompresseur et procede d'obtention
FR2742391B1 (fr) Mecanisme de reglage de phare et procede pour en assurer l'etancheite
FR2773558B1 (fr) Procede pour l'obtention de 1-butene
EP1230922A4 (fr) Agents favorisant l'engraissement d'animaux et procede favorisant l'engraissement
FR2754208B1 (fr) Dispositif pour la decoupe de pieces de forme quelconque
ID21901A (id) Proses pembuatan garam-garam hidroksilamonium
EP0831935A4 (fr) Agents de contraste ultrasonore gazeux et procede associe
FR2738902B1 (fr) Procede pour eviter la formation de givre dans un appareil produisant de la glace
EP1573808A4 (fr) Procede de creation de motif de paves de remplissage pour ci, ci resultant et procede d'analyse
FR2757348B1 (fr) Composition de litiere pour animaux et son procede d'obtention
EP0795753A4 (fr) Procede de determination quantitative de bilirubine

Legal Events

Date Code Title Description
TP Transmission of property